Incyte Corporation Settles Royalty Dispute with Novartis, Agrees to $280 Million Payment and Reduced Future Royalties

Reuters

05-14

Incyte Corporation Settles Royalty Dispute with Novartis, Agrees to $280 Million Payment and Reduced Future Royalties

Incyte Corporation has announced a significant development in its business relationship with Novartis Pharma AG. On May 11, 2025, the two companies reached a settlement agreement concerning a dispute over royalty payments related to the drug JAKAFI. Under the terms of the agreement, Incyte will pay Novartis $280 million to settle disputed royalties on U.S. sales of JAKAFI through December 31, 2024. Additionally, the royalty rate on future net sales of JAKAFI in the United States will be reduced by 50% starting January 1, 2025, for a period specified in the Settlement Agreement. This adjustment will result in a reduced royalty payment of approximately $14.9 million for the quarter ending March 31, 2025. The financial implications of this settlement will be reflected in Incyte's financial statements for the quarter ending June 30, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-25-000059), on May 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535253200"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535253200\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535253200?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535253200","market":"nz","top_or_hot":-1,"title":"Incyte Corporation Settles Royalty Dispute with Novartis, Agrees to $280 Million Payment and Reduced Future Royalties","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Corporation Settles Royalty Dispute with Novartis, Agrees to $280 Million Payment and Reduced Future Royalties\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced a significant development in its business relationship with Novartis Pharma AG. On May 11, 2025, the two companies reached a settlement agreement concerning a dispute over royalty payments related to the drug JAKAFI. Under the terms of the agreement, Incyte will pay Novartis $280 million to settle disputed royalties on U.S. sales of JAKAFI through December 31, 2024. Additionally, the royalty rate on future net sales of JAKAFI in the United States will be reduced by 50% starting January 1, 2025, for a period specified in the Settlement Agreement. This adjustment will result in a reduced royalty payment of approximately $14.9 million for the quarter ending March 31, 2025. The financial implications of this settlement will be reflected in Incyte's financial statements for the quarter ending June 30, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-25-000059), on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Corporation Settles Royalty Dispute with Novartis, Agrees to $280 Million Payment and Reduced Future Royalties</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Corporation Settles Royalty Dispute with Novartis, Agrees to $280 Million Payment and Reduced Future Royalties\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 19:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Corporation Settles Royalty Dispute with Novartis, Agrees to $280 Million Payment and Reduced Future Royalties\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced a significant development in its business relationship with Novartis Pharma AG. On May 11, 2025, the two companies reached a settlement agreement concerning a dispute over royalty payments related to the drug JAKAFI. Under the terms of the agreement, Incyte will pay Novartis $280 million to settle disputed royalties on U.S. sales of JAKAFI through December 31, 2024. Additionally, the royalty rate on future net sales of JAKAFI in the United States will be reduced by 50% starting January 1, 2025, for a period specified in the Settlement Agreement. This adjustment will result in a reduced royalty payment of approximately $14.9 million for the quarter ending March 31, 2025. The financial implications of this settlement will be reflected in Incyte's financial statements for the quarter ending June 30, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-25-000059), on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDLbxCPVw:1","article_id":"2535253200","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535253200","pubTimestamp":1747223649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incyte Corporation has announced a significant development in its business relationship with Novartis Pharma AG. On May 11, 2025, the two companies reached a settlement agreement concerning a dispute over royalty payments related to the drug JAKAFI. Under the terms of the agreement, Incyte will pay Novartis $280 million to settle disputed royalties on U.S. sales of JAKAFI through December 31, 2024. Additionally, the royalty rate on future net sales of JAKAFI in the United States will be reduced by 50% starting January 1, 2025, for a period specified in the Settlement Agreement. This adjustment will result in a reduced royalty payment of approximately $14.9 million for the quarter ending March 31, 2025. The financial implications of this settlement will be reflected in Incyte's financial statements for the quarter ending June 30, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4588":"碎股","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗"},"translate_title":"Incyte Corporation解决与诺华的特许权使用费纠纷，同意支付2.8亿美元并减少未来的特许权使用费","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"Incyte Corporation Settles Royalty Dispute with Novartis, Agrees to $280 Million Payment and Reduced Future Royalties\n    \n\n        Incyte Corporation has announced a significant development in its business relationship with Novartis Pharma AG. On May 11, 2025, the two companies reached a settlement agreement concerning a dispute over royalty payments related to the drug JAKAFI. Under the terms of the agreement, Incyte will pay Novartis $280 million to settle disputed royalties on U.S. sales of JAKAFI through December 31, 2024. Additionally, the royalty rate on future net sales of JAKAFI in the United States will be reduced by 50% starting January 1, 2025, for a period specified in the Settlement Agreement. This adjustment will result in a reduced royalty payment of approximately $14.9 million for the quarter ending March 31, 2025. The financial implications of this settlement will be reflected in Incyte's financial statements for the quarter ending June 30, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-25-000059), on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}